Adipose Stem Cells Converted to Hematopoietic Cells
Summary
USPTO published patent application US20260109947A1, filed March 11, 2024, for a method of producing hematopoietic stem/progenitor cells (HS/PCs) and blood cells from adipose-derived mesenchymal stem cells (Ad MSCs). The method involves obtaining and expanding biological cells, isolating a pure Ad MSC cell line, converting it to HS/PCs in vitro, and expanding the resulting cells. This publication represents the first entry in the patent record for the named inventors Wei LI, Shaojin YOU, Michael Chengnan LIN, and Annie YOU; no compliance obligations or deadlines are created.
“A method of producing hematopoietic stem/progenitor cells (HS/PCs) and blood cells from adipose derived mesenchymal stem cells (Ad MSCs).”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 264 changes logged to date.
What changed
USPTO published patent application US20260109947A1, filed March 11, 2024, covering a method for producing hematopoietic stem/progenitor cells and blood cells from adipose-derived mesenchymal stem cells. The application names four inventors and provides CPC classifications indicating its placement within bioprocessing and cell culture technology subclasses.
Affected parties in the biotechnology and cell therapy sector should monitor this application as it may signal competitive patent activity in the HS/PC expansion space. Parties developing similar stem cell differentiation protocols should evaluate freedom-to-operate implications. No immediate compliance obligations arise from this publication.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
System and Method For Converting Adipose Derived Mesenchymal Stem Cells To Hematopoietic Stem/Progenitor Cells And Differentiating Into Blood Cells And Applications Of Same
Application US20260109947A1 Kind: A1 Apr 23, 2026
Inventors
Wei LI, Shaojin YOU, Michael Chengnan LIN, Annie YOU
Abstract
A method of producing hematopoietic stem/progenitor cells (HS/PCs) and blood cells from adipose derived mesenchymal stem cells (Ad MSCs). The method comprises obtaining biological cells of a subject; expanding the biological cells; obtaining a pure Ad MSCs cell line from the expanded biological cells; converting the pure Ad MSCs cell line into HS/PCs in vitro; expanding the converted HS/PCs in vitro; and obtaining the expanded HS/PCs.
CPC Classifications
C12N 5/0634 C12M 33/04 C12M 41/44 C12M 41/48 C12M 45/02 C12N 2500/24 C12N 2500/84 C12N 2501/105 C12N 2501/125 C12N 2501/145 C12N 2501/148 C12N 2501/15 C12N 2501/16 C12N 2501/165 C12N 2501/22 C12N 2501/23 C12N 2501/26 C12N 2501/33 C12N 2501/999 C12N 2506/1384
Filing Date
2024-03-11
Application No.
19159977
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.